ciglitazone has been researched along with gw 1929 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blanchard, SG; Brackeen, MF; Brown, KK; Cobb, JE; Collins, JL; Harrington, WW; Hashim, MA; Henke, BR; Hull-Ryde, EA; Kaldor, I; Kliewer, SA; Lake, DH; Leesnitzer, LM; Lehmann, JM; Lenhard, JM; Miller, JF; Mook, RA; Noble, SA; Oliver, W; Orband-Miller, LA; Parks, DJ; Plunket, KD; Szewczyk, JR; Willson, TM | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Chi, KH; Chio, CC; Huang, WC; Lin, WW; Wu, HM | 1 |
| Han, S; Huang, RP; Sidell, N; Wanichkul, T | 1 |
| Amodeo, V; Bazan, V; Caruso, S; Cicero, G; Contaldo, C; Corsini, LR; Fanale, D; Fiorio, E; Insalaco, L; Lo Re, G; Mercanti, A; Russo, A; Surmacz, E; Terrasi, M | 1 |
5 other study(ies) available for ciglitazone and gw 1929
| Article | Year |
|---|---|
N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
Topics: Administration, Oral; Aminopyridines; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; DNA-Binding Proteins; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Ligands; Lipids; Male; Mice; Oxazoles; Propionates; Radioligand Assay; Rats; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Stereoisomerism; Structure-Activity Relationship; Transcription Factors; Transfection; Tyrosine | 1998 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Superoxide anion-dependent Raf/MEK/ERK activation by peroxisome proliferator activated receptor gamma agonists 15-deoxy-delta(12,14)-prostaglandin J(2), ciglitazone, and GW1929.
Topics: Animals; Benzophenones; Cell Line; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Peroxisomes; Phosphatidylinositol 3-Kinases; Phosphorylation; Prostaglandin D2; Protein Kinase C; Proto-Oncogene Proteins c-raf; ras Proteins; Reactive Oxygen Species; Receptors, Cytoplasmic and Nuclear; Superoxides; Thiazoles; Thiazolidinediones; Transcription Factors; Tyrosine | 2002 |
Cytokine regulation by peroxisome proliferator-activated receptor gamma in human endometrial cells.
Topics: Benzophenones; Colony-Stimulating Factors; Cytokines; Endometrium; Epithelial Cells; Female; Humans; Interleukin-6; Ligands; Phenylacetates; Prostaglandin D2; Protein Array Analysis; Protein Isoforms; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Tyrosine | 2003 |
Effects of PPARĪ³ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells.
Topics: Benzophenones; Binding Sites; Breast Neoplasms; Cell Movement; Cell Survival; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Leptin; Ligands; MCF-7 Cells; PPAR gamma; Promoter Regions, Genetic; RNA, Messenger; Sp1 Transcription Factor; Thiazolidinediones; Tyrosine; Vascular Endothelial Growth Factor A | 2013 |